Highlights

  • Second quarter 2026 net sales rose 14% to $872.3 million, or 12.7% organically excluding currency effects.
  • GAAP diluted earnings per share were $2.15 versus $1.82, while non-GAAP adjusted diluted EPS was $2.37 versus $1.84.
  • West disclosed a material May 2026 cyberattack that disrupted operations, cutting West Vantage sales growth by about $7 million.
  • The company repurchased 1,760,610 shares for $454.3 million in six months under a $1.0 billion program authorized in February.

West Pharmaceutical Services (NYSE:WST) shares were trading near their 52-week high at USD 394.97 on October 21, 2026, up 1.59%. The injectable drug packaging maker authorized a $1.0 billion buyback in February, experienced a material cybersecurity attack in May, and reported second quarter 2026 results in a quarterly report filed July 23.

Based in Exton, Pennsylvania, West is a Pennsylvania corporation and describes itself as a leading global manufacturer of integrated containment and delivery systems for injectable drugs and healthcare products. It reports two segments: Proprietary Products, which offers packaging, containment solutions, drug delivery systems and analytical lab services, mainly to biologic, generic and pharmaceutical customers; and West Vantage, which designs, manufactures and assembles complex devices and combination products. Its fiscal year ends December 31. West also holds a 49% interest in Daikyo, with which it shares technologies and distribution.

Net Sales Up 14% on High-Value Products

Net sales for the quarter ended June 30, 2026 were $872.3 million, compared with $766.5 million a year earlier. Volume and mix added $67.0 million and price increases $30.3 million, and currency added $8.5 million. Proprietary Products sales rose 16.6% to $722.6 million. High-value product (HVP) components grew 18.4% excluding currency, which the company tied to demand for biologics and GLP-1 products and to price increases. HVP delivery devices grew 29.2%, led by self-injection devices, including SmartDose 3.5mL ahead of the July 2026 transaction closing. West Vantage sales rose 2.0% to $149.7 million.

Consolidated gross margin widened to 37.7% from 35.7%. GAAP operating profit was $179.1 million versus $153.7 million, and net income was $154.0 million versus $131.8 million. Non-GAAP adjusted operating profit was $197.4 million. West Vantage was weaker: its gross profit fell 17.2% to $21.2 million and its operating profit fell 27.5%, which the company mainly linked to production downtime from the cyber incident. Corporate and unallocated SG&A rose 45.3%, including $6.9 million of nonrecurring professional fees tied to legal matters and the incident, and $5.1 million for the SmartDose sale and other M&A work.

For six months, net sales were $1,717.2 million, up 17.3%, and GAAP diluted EPS was $4.07 against $3.05.

Cyber Incident, SmartDose Sale and Capital Returns

In May 2026, West said unauthorized parties exfiltrated certain data and encrypted certain systems. It took systems offline globally, notified law enforcement, and engaged outside forensic experts. The incident temporarily disrupted global operations, but the company says it has been contained and operations have fully recovered. It carries cybersecurity insurance, though it cautions that coverage may not be sufficient for every loss.

In December 2025, West agreed to sell manufacturing and supply rights for the SmartDose 3.5mL On-Body Delivery System and related facilities to AbbVie for $112.5 million, subject to adjustments. The related restructuring plan is expected to cost $12 million to $16 million, with annualized savings of $15 million to $20 million over about twelve to fifteen months. On July 14, 2026, West and Daikyo signed amended technology and distribution agreements with ten-year terms.

Cash and cash equivalents were $435.8 million at June 30, down from $791.3 million at year end, mainly from buybacks and capital spending. Operating cash flow was $213.9 million versus $306.5 million, and capital expenditures were $85.9 million versus $146.5 million. Debt was $202.9 million, with no borrowings on the revolving credit facility and $497.7 million available. West is also defending a securities class action filed in 2025 that covers purchases from February 16, 2023 to February 12, 2025.

Outlook and Items to Watch

The quarterly report does not include numeric financial guidance. West says it does not expect tariff developments, including refunds it began receiving in the second quarter under the IEEPA ruling, or the Middle East conflict to have a material effect on 2026 results. The SmartDose restructuring is scheduled over twelve to fifteen months from its December 2025 approval, and the buyback has no expiration date. These statements are company expectations.